Roger S. McIntyre, MD, FRCPC

Department of Psychiatry, University of Toronto, Toronto, Canada; Department of Pharmacology, University of Toronto, Toronto, Canada; Brain and Cognition Discovery Foundation, Toronto, Canada.

JCP
Original Research

February 23, 2021

Even given known risk factors for suicide, predicting suicide is difficult. This study used deep learning of structural magnetic resonance imaging to create an algorithm for detecting suicidal ideation...
Vincent Chin-Hung Chen, Fu-Te Wong, Yuan-Hsiung Tsai, et al
PCC
Original Research

September 17, 2020

Bipolar disorder is characterized by a chronic and subtle course of fluctuating symptoms. To explore the efficacy of cariprazine across the symptoms of bipolar depression, post hoc analyses of...
Lakshmi N. Yatham, Eduard Vieta, Roger S. McIntyre, et al
JCP
Correction

April 22, 2020

Joshua D. Rosenblat, Andre F. Carvalho, Madeline Li, et al
JCP
Letter to the Editor

January 28, 2020

 Rosenblat and McIntyre reply to the letter "Sublingual Ketamine: An Option for Increasing Accessibility of Ketamine Treatments for Depression?" by Swainson and Khullar.
Joshua D. Rosenblat, Roger S. McIntyre
JCP
Consensus Statement

January 28, 2020

Tardive dyskinesia remains a serious complication associated with dopamine receptor blocking agents. In this article, read guidance from experts on best practices for tardive dyskinesia screening, diagnosis, and treatment.
Stanley N. Caroff, Leslie Citrome, Jonathan Meyer, et al
JCP
The Differential Diagnosis of MDD Versus BP
Academic Highlights

May 14, 2019

Given the similarity in clinical presentation between major depressive disorder (MDD) and the depressive episodes of bipolar disorder (BP), misdiagnoses occur too often. Read this Academic Highlights to learn...
Roger S. McIntyre, Mark Zimmerman, Joseph F. Goldberg, et al
JCP
Original Research

May 14, 2019

Find out in this population-based NHIRD study which treatments used for psoriasis can also stave off dementia, another inflammatory disease, and whether the type of dementia is a key...
Kuan-Lun Huang, Chiung-Chi Yeh, Shu-I Wu, et al
JCP
Activating and Sedating Properties of Medications Used for MDD
Academic Highlights

April 30, 2019

Some antipsychotics used to treat MDD are associated with activating or sedating effects. In this Academic Highlights, 4 experts offer clinical insights into the impact of these effects on...
Leslie L. Citrome, Roger S. McIntyre, J. Sloan Manning, et al
JCP
Review Article

April 16, 2019

Intravenous ketamine has rapid and robust antidepressant effects. Read this systematic review to learn if oral ketamine also has efficacy and tolerability in depressed individuals.
Joshua D. Rosenblat, Andre F. Carvalho, Madeline Li, et al
JCP
Educational Activity

February 20, 2019

Despite the availability of effective treatments for MDD, many individuals have difficulty achieving remission. Residual symptoms can be difficult to differentiate from treatment side effects. Through 2 comic-based case...
Roger S. McIntyre
PCC
Article

November 1, 2018

What patient-reported factors influence medication treatment decisions among individuals with bipolar and unipolar depression? The authors of this article conducted a survey to answer this question. Their findings may...
Joshua D. Rosenblat, Gregory E. Simon, Gary S. Sachs, et al
JCP
Review Article

May 1, 2018

A variety of pharmacologic agents are available for treating your patients with bipolar disorder, but have you considered adding psychoeducation to your armamentarium? This review summarizes the evidence on...
Ann Soo, Zhong Wei Zhang, Sarah Jia' En Khong, et al

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe